Furthermore, an increase in SEC23A expression could also compensate for the function of mutated SEC23B in CDAII patients, a potential therapeutic strategy for CDAII patients 45, 46. The gene discussed is SEC23A; the disease is congenital dyserythropoietic anemia type 2.